PMC10196488_01
Computed tomography scan (CT scan) regarding the clinical response during whole course of treatment. (A) Baseline CT scan in February 2017. (B) CT scan after adjuvant CAPOX in June 2017. (C) CT scan after 1 year of dabrafenib, trametinib, and cetuximab in October 2018.
fonc-13-1166545-g001.jpg
PMC10196488_01_fonc-13-1166545-g001.jpg
f1
On the computer tomography scan (CT scan), one suspicious lesion in the liver with a diameter of 3 cm and a suspicious mass in the colon descendens were described ( Figure 1 ). The CT scan showed five new liver metastases without further metastases in other organs ( Figure 1 ), and the tumor marker carcinoembryonic antigen (CEA) was elevated. In August 2018, no further progression was detected on the CT scan ( Figure 1 ), and in October 2018, a PET/CT showed a CR.
Pronounced skin toxicity due to cetuximab therapy.
fonc-13-1166545-g002.jpg
PMC10196488_01_fonc-13-1166545-g002.jpg
f2
Figure 2 ), steroid-containing cream and 100 mg of minocycline per day were prescribed, and cetuximab therapy was temporarily stopped. Furthermore, the patient suffered from recurrent urinary tract infections due to mucosal toxicity requiring antibiotic therapy in the early stages to prevent urosepsis.
Flowchart of the whole course of treatment.
fonc-13-1166545-g003.jpg
PMC10196488_01_fonc-13-1166545-g003.jpg
f3
Until January 2023, the patient is still in CR and in excellent general condition.  Figure 3  shows an overview of the whole course of treatment in this patient, and  Figure 4  shows the changes in the tumor marker during the therapy.
Line chart of the changes of the tumor marker CEA during the process of the treatment since February 2017. CEA, carcinoembryonic antigen.
fonc-13-1166545-g004.jpg
PMC10196488_01_fonc-13-1166545-g004.jpg
f4
Until January 2023, the patient is still in CR and in excellent general condition.  Figure 3  shows an overview of the whole course of treatment in this patient, and  Figure 4  shows the changes in the tumor marker during the therapy.